Recombinant Vaccines Market Report 2026

Recombinant Vaccines Market Overview

• Recombinant Vaccines market size has reached to $15.79 billion in 2025 • Expected to grow to $28.07 billion in 2030 at a compound annual growth rate (CAGR) of 12.2% • Growth Driver: Increasing Prevalence Of Infectious Diseases Is Fueling The Growth Of The Market Due To Rising Incidence Of Sexually Transmitted Infections And Ongoing Public Health Challenges • Market Trend: Advancements In Recombinant HPV Vaccine REC603 And Operational Performance • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Recombinant Vaccines Market?

Recombinant vaccines refer to vaccines developed using advanced Recombinant DNA Technology, in which specific genes encoding protective antigens from a pathogen are inserted into a safe host organism to produce highly purified proteins that effectively stimulate a targeted immune response. These vaccines provide precise, safe, and long-lasting protection by activating the body’s immune system without exposing it to the complete disease-causing microorganism, thereby significantly reducing the risk of infection and adverse reactions. The main types of recombinant vaccines include subunit vaccines and vector-based vaccines. Subunit vaccines refer to vaccines that contain purified pieces of the pathogen, such as proteins, to stimulate an immune response without using live components. These vaccines are developed for disease indications including human papillomavirus, herpes zoster, hepatitis B, and other diseases. They are administered via routes such as parenteral and other routes of administration, and are used by end users including pediatric and adult populations.

What Is The Recombinant Vaccines Market Growth Forecast?

The recombinant vaccines market size is expected to see rapid growth in the next few years. It will grow to $28.07 billion in 2030 at a compound annual growth rate (CAGR) of 12.2%. The growth in the forecast period can be attributed to growing demand for precision vaccines, expansion of emerging disease vaccines, rising adult booster programs, increasing global immunization coverage, strong pipeline of recombinant candidates. Major trends in the forecast period include increase in recombinant subunit vaccines, expansion of vector based vaccine platforms, higher adult immunization programs, growth in combination recombinant vaccines, rising focus on long duration immunity.

Global Recombinant Vaccines Market Segmentation

1) By Type: Subunit Vaccines; Vector-Based Vaccines 2) By Disease Indication: Human Papillomavirus (HPV); Herpes Zoster; Hepatitis B; Other Diseases 3) By Route Of Administration: Parenteral; Other Route Of Administrations 4) By End User: Pediatric; Adults Subsegments: 1) By Subunit Vaccines: Protein Subunit Vaccines; Polysaccharide Subunit Vaccines; Conjugate Subunit Vaccines; Glycopeptide Subunit Vaccines; Recombinant Subunit Vaccines 2) By Vector-Based Vaccines: Viral Vector Vaccines; Non Viral Vector Vaccines; Replicating Vector Vaccines; Non Replicating Vector Vaccines; Bacterial Vector Vaccines

What Is The Driver Of The Recombinant Vaccines Market?

The increasing prevalence of infectious diseases is expected to propel the growth of the recombinant vaccines market going forward. An infectious disease is a disease that is caused by germs (microorganisms) such as bacteria, viruses, fungi, or parasites and can spread from one person to another, directly or indirectly. The prevalence of infectious diseases is growing due to poor sanitation and hygiene, as inadequate access to clean water, proper sanitation facilities, and effective waste management leads to the easy spread of harmful microorganisms through contaminated food, water, and personal contact, thereby increasing the risk of infections. Recombinant vaccines help prevent infectious diseases by using biologically engineered genetic material from pathogens to stimulate an immune response without causing illness. For instance, in July 2024, according to the Australian Institute of Health and Welfare, an Australia-based national agency, over 109,000 chlamydia and more than 40,000 gonorrhea notifications were recorded as the most commonly reported sexually transmitted infections in Australia in 2023, along with more than 6,400 infectious syphilis cases, highlighting the increased incidence and ongoing public health challenges. Therefore, the increasing prevalence of infectious diseases is driving the growth of the recombinant vaccines industry.

Key Players In The Global Recombinant Vaccines Market

Major companies operating in the recombinant vaccines market are Johnson And Johnson, Merck And Co Inc., Pfizer Inc., Sanofi S. A., Novartis AG, AstraZeneca Plc, GlaxoSmithKline Plc, Mitsubishi Chemical Group Corporation, CSL Limited, Sinovac Biotech Ltd., Boehringer Ingelheim International GmbH, Zoetis Services Llc, Elanco Animal Health, BioNTech Se, Green Cross Corporation (Gc Biopharma), Bavarian Nordic A S, VBI Vaccines Inc., Vaxart Inc., Biological E Limited, Novavax Inc., Serum Institute Of India Private Limited, Vaxcyte Inc., Bharat Biotech International Limited, and Transgene S A.

Global Recombinant Vaccines Market Trends and Insights

Major companies operating in the recombinant vaccines market are focusing on developing novel vaccines, such as the recombinant 9-valent HPV vaccine, to gain a competitive edge in the market. The recombinant 9-valent HPV vaccine is a vaccine that protects against nine types of human papillomavirus (HPV) and is made using recombinant DNA technology, which means it is produced in the laboratory without using live virus and helps prevent HPV-related diseases such as cervical cancer and genital warts. For instance, in August 2023, Jiangsu Recbio Technology Co. Ltd., a China-based biopharmaceutical company, advanced REC603, its recombinant 9-valent HPV vaccine, through Phase III clinical follow-up with ongoing 24-month observations. The vaccine demonstrated strong immunogenicity, a favorable safety profile, scalable manufacturing potential, and long-term efficacy, supporting its potential for broad HPV prevention and commercialization.

What Are Latest Mergers And Acquisitions In The Recombinant Vaccines Market?

In December 2025, Sanofi S.A., a France-based biopharmaceutical company, acquired Dynavax Technologies for an undisclosed amount. Through this acquisition, Sanofi aims to strengthen its adult immunization portfolio by integrating Dynavax’s marketed HEPLISAV-B recombinant hepatitis B vaccine, its phase 1/2 shingles candidate, and other pipeline assets, enhancing global vaccine development, commercial reach, and innovation in recombinant vaccines. Dynavax Technologies Corporation is a US-based company specializing in developing and commercializing recombinant vaccines for the prevention of infectious diseases, including hepatitis B and shingles.

Regional Insights

North America was the largest region in the recombinant vaccines market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Recombinant Vaccines Market?

The recombinant vaccines market consists of sales of recombinant hepatitis B vaccines, recombinant human papillomavirus vaccines, recombinant influenza vaccines, recombinant meningococcal vaccines, recombinant dengue vaccines, recombinant malaria vaccines, and recombinant shingles vaccines. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Recombinant Vaccines Market Report 2026?

The recombinant vaccines market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the recombinant vaccines industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.